This review discusses colorectal adenocarcinoma, one of the most common cancers worldwide, with increasing diagnoses and high mortality rates despite therapeutic advancements. Precision medicine plays a crucial role in treatment, with a focus on genetic mutations such as KRAS, NRAS, and BRAF, and microsatellite instability. Targeted therapies and immune checkpoint inhibitors are tailored based on the tumor's molecular profile, significantly improving survival rates. Trifluridine/tipiracil, regorafenib, and fruquintinib are effective in advanced stages, though with limited response rates. The importance of genomics and personalized treatment is emphasized, with biomarkers like KRASG12 mutations affecting overall survival outcomes.
Colorectal Adenocarcinoma in Precision Medicine / Cirolla, Virginia A.. - In: INTERNATIONAL JOURNAL OF CONTEMPORARY RESEARCH IN MULTIDISCIPLINARY. - ISSN 2583-7397. - 4:4(2025), pp. 147-150. [10.5281/zenodo.14901271]
Colorectal Adenocarcinoma in Precision Medicine
Virginia A. Cirolla
Primo
Membro del Collaboration Group
2025
Abstract
This review discusses colorectal adenocarcinoma, one of the most common cancers worldwide, with increasing diagnoses and high mortality rates despite therapeutic advancements. Precision medicine plays a crucial role in treatment, with a focus on genetic mutations such as KRAS, NRAS, and BRAF, and microsatellite instability. Targeted therapies and immune checkpoint inhibitors are tailored based on the tumor's molecular profile, significantly improving survival rates. Trifluridine/tipiracil, regorafenib, and fruquintinib are effective in advanced stages, though with limited response rates. The importance of genomics and personalized treatment is emphasized, with biomarkers like KRASG12 mutations affecting overall survival outcomes.| File | Dimensione | Formato | |
|---|---|---|---|
|
IJCRM20254137.pdf
accesso aperto
Note: Colorectal Adenocarcinoma in Precision Medicine Virginia A. Cirolla1* 1MD, PhD in Oncology, UOC Oncology La Sapienza University of Rome, Italy Corresponding Author: *Virginia A. Cirolla DOI: https://doi.org/10.5281/zenodo.14901272 Abstract Manuscript Information This review discusses colorectal adenocarcinoma, one of the most common cancers worldwide, with increasing diagnoses and high mortality rates despite therapeutic advancements. Precision medicine plays a crucial role in treatment, with a focus on genetic mutations such as KRAS, NRAS, and BRAF, and microsatellite instability. Targeted therapies and immune checkpoint inhibitors are tailored based on the tumor's molecular profile, significantly improving survival rates. Trifluridine/tipiracil, regorafenib, and fruquintinib are effective in advanced stages, though with limited response rates. The importance of genomics and personalized treatment is emphasized, with biomarkers like KRASG12 mutations affecting overall survival outcomes.
Tipologia:
Documento in Pre-print (manoscritto inviato all'editore, precedente alla peer review)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
849.63 kB
Formato
Adobe PDF
|
849.63 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
